DURHAM, N.C., Sept. 20, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced today that its Chief Scientific Officer and Vice President, Research and Development, Charles Nicolette, PH.D., is presenting at BIOX: Noble Financial Capital Markets' Life Sciences Exposition to be held at the University of Connecticut, Stamford, Conn., on September 24-25, 2012.
Dr. Nicolette will be speaking on the "Innovation in Immunotherapy & Vaccines" panel, joined by Dr. Phil Greenberg, Head of the Program in Immunology at the Fred Hutchinson Cancer Research Center and representatives from other biotech and pharmaceutical companies in the immunotherapy and vaccine space. In addition to discussion surrounding the recent renewed industry interest in immunotherapy, Dr. Nicolette will provide an overview of Argos' proprietary Arcelis platform technology, the Company's Phase 3 trial design for its fully personalized active immunotherapy AGS-003, for the treatment of metastatic renal cell carcinoma, and the therapy's mechanism of action as it correlates to immune response and survival outcomes.
Event: BIOX: Noble Financial Capital Markets' Life Sciences Exposition
Date: Monday, September 24, 2012
Time: 5:55 pm ET
About the Arcelis™ Technology
Arcelis is a fully personalized, active immunotherapy technology that captures all antigens, including mutated and variant antigens that are specific to each patient´s disease. It has been shown to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that are associated with toxicity. The technology can be leveraged to manufacture personalized therapies for any cancer or infectious disease.
The Arcelis process integrates readily into many current treatment paradigms, using only a small tumor or blood sample and the patient´s own dendritic cells, which are derived and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient sample to program the dendritic cells to target the entire disease-antigen repertoire. The activated, antigen-loaded dendritic cells are then formulated into the patient´s plasma and administered as an injection into the skin to produce the desired patient-specific immune response.
Arcelis technology also overcomes many of the manufacturing and commercialization challenges that have impeded other cancer immunotherapies. Automated processes allow a single facility to serve all of North America and can be used to treat any cancer or infectious disease with the same manufacturing process and equipment.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate AGS-003 has initiated a Phase 3 study for the treatment of mRCC, and the Company plans to have data from its Phase 2b study of AGS-004 for the treatment of HIV in the second half of 2013. Argos also recently completed a successful Phase 1a study of AGS-009 in patients with lupus.